Rafael Tourinho-Barbosa
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Rafael Tourinho-Barbosa has a total of 64 co-authors. Here are the top co-authors by number of shared publications:
- Fernando Korkes
Centro Universitário FMABC, Santo Andre, SP, Brazil
2 shared publications - Rafael Sanchez-Salas
Department of Urology, Institut Mutualiste Montsouris, Paris, France
2 shared publications Xavier Cathelineau
Department of Urology Institut Mutualiste Montsouris, Université Paris‐Descartes Paris France
2 shared publications- Andre Luis Abreu
Keck Medical Center of USC, USC Institute of Urology, University of Southern California, Los Angeles, CA 90033, USA
1 shared publication - Annabel Howitt
Affiliation General Surgery, Bradford Teaching Hospitals, Bradford, United Kingdom
1 shared publication Annick Mombet
Department of Urology Institut Mutualiste Montsouris, Université Paris‐Descartes Paris France
1 shared publication
Latest Publications
- 30 October 2023
- Published by Wiley in The Prostate
- Vol. 84 (2) , 158-165
Assessing the efficacy of pelvic floor muscle training and duloxetine on urinary continence recovery following radical prostatectomy: A randomized clinical trial
Background: Urinary incontinence (UI) can negatively impact quality of life (QoL) after robot‐assisted radical prostatectomy (RARP). Pelvic floor muscle training (PFMT) and duloxetine are used to manage post‐RARP UI, but their efficacy remains uncertain. We aimed to investigate the efficacy of PFMT and duloxetine in promoting urinary continence recovery (UCR) after RARP.Methods: A randomized controlled trial involving patients with urine leakage after RARP from May 2015 to February 2018. Patients were randomized into 1 of 4 arms: (1) PFMT‐biofeedback, (2) duloxetine, (3) combined PFMT‐biofeedback and duloxetine, (4) control arm. PFMT consisted of pelvic muscle exercises conducted with electromyographic feedback weekly, for 3 months. Oral duloxetine was administered at bedtime for 3 months. The primary outcome was prevalence of continence at 6 months, defined as using ≤1 security pad. Urinary symptoms and QoL were assessed by using a visual analogue scale, and validated questionnaires.Results: From the 240 patients included in the trial, 89% of patients completed 1 year of follow‐up. Treatment compliance was observed in 88% (92/105) of patients receiving duloxetine, and in 97% (104/107) of patients scheduled to PFMT‐biofeedback sessions. In the control group 96% of patients had achieved continence at 6 months, compared with 90% (p = 0.3) in the PMFT‐biofeedback, 73% (p = 0.008) in the duloxetine, and 69% (p = 0.003) in the combined treatment arm. At 6 months, QoL was classified as uncomfortable or worse in 17% of patients in the control group, compared with 44% (p = 0.01), 45% (p = 0.008), and 34% (p = 0.07), respectively. Complete preservation of neurovascular bundles (NVB) (OR: 2.95; p = 0.048) was the only perioperative intervention found to improve early UCR.Conclusions: PFMT‐biofeedback and duloxetine demonstrated limited impact in improving UCR after RP. Diligent NVB preservation, along with preoperative patient and disease characteristics, are the primary determinants for early UCR.
- 30 October 2023
- Published by Wiley in The Prostate
- Vol. 84 (2) , 158-165
Assessing the efficacy of pelvic floor muscle training and duloxetine on urinary continence recovery following radical prostatectomy: A randomized clinical trial
Background: Urinary incontinence (UI) can negatively impact quality of life (QoL) after robot‐assisted radical prostatectomy (RARP). Pelvic floor muscle training (PFMT) and duloxetine are used to manage post‐RARP UI, but their efficacy remains uncertain. We aimed to investigate the efficacy of PFMT and duloxetine in promoting urinary continence recovery (UCR) after RARP.Methods: A randomized controlled trial involving patients with urine leakage after RARP from May 2015 to February 2018. Patients were randomized into 1 of 4 arms: (1) PFMT‐biofeedback, (2) duloxetine, (3) combined PFMT‐biofeedback and duloxetine, (4) control arm. PFMT consisted of pelvic muscle exercises conducted with electromyographic feedback weekly, for 3 months. Oral duloxetine was administered at bedtime for 3 months. The primary outcome was prevalence of continence at 6 months, defined as using ≤1 security pad. Urinary symptoms and QoL were assessed by using a visual analogue scale, and validated questionnaires.Results: From the 240 patients included in the trial, 89% of patients completed 1 year of follow‐up. Treatment compliance was observed in 88% (92/105) of patients receiving duloxetine, and in 97% (104/107) of patients scheduled to PFMT‐biofeedback sessions. In the control group 96% of patients had achieved continence at 6 months, compared with 90% (p = 0.3) in the PMFT‐biofeedback, 73% (p = 0.008) in the duloxetine, and 69% (p = 0.003) in the combined treatment arm. At 6 months, QoL was classified as uncomfortable or worse in 17% of patients in the control group, compared with 44% (p = 0.01), 45% (p = 0.008), and 34% (p = 0.07), respectively. Complete preservation of neurovascular bundles (NVB) (OR: 2.95; p = 0.048) was the only perioperative intervention found to improve early UCR.Conclusions: PFMT‐biofeedback and duloxetine demonstrated limited impact in improving UCR after RP. Diligent NVB preservation, along with preoperative patient and disease characteristics, are the primary determinants for early UCR.
- Open Access
- 22 September 2022
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 17 (9) , e0272446
An international consensus for mitigation of the detrimental effects of the COVID-19 pandemic on laparoscopic training
Achieve an international consensus on how to recover lost training opportunities. The results of this study will help inform future EAES guidelines about the recovery of surgical training before and after the pandemic. A global survey conducted by our team demonstrated significant disruption in surgical training during the COVID-19 pandemic. This was wide-spread and affected all healthcare systems (whether insurance based or funded by public funds) in all participating countries. Thematic analysis revealed the factors perceived by trainees as barriers to training and gave birth to four-point framework of recovery. These are recommendations that can be easily achieved in any country, with minimal resources. Their implementation, however, relies heavily on the active participation and leadership by trainers. Based on the results of the global trainee survey, the authors would like to conduct a Delphi-style survey, addressed to trainers on this occasion, to establish a pragmatic step-by-step approach to improve training during and after the pandemic. This will be a mixed qualitative and quantitative study. Semi-structured interviews will be performed with laparoscopic trainers. These will be transcribed and thematic analysis will be applied. A questionnaire will then be proposed; this will be based on both the results of the semi structured interviews and of the global trainee survey. The questionnaire will then be validated by the steering committee of this group (achieve consensus of >80%). After validation, the questionnaire will be disseminated to trainers across the globe. Participants will be asked to consent to participate in further cycles of the Delphi process until more than 80% agreement is achieved. This study will result in a pragmatic framework for continuation of surgical training during and after the pandemic (with special focus on minimally invasive surgery training).
- 22 September 2022
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 17 (9) , e0272446
Open AccessAn international consensus for mitigation of the detrimental effects of the COVID-19 pandemic on laparoscopic training
Achieve an international consensus on how to recover lost training opportunities. The results of this study will help inform future EAES guidelines about the recovery of surgical training before and after the pandemic. A global survey conducted by our team demonstrated significant disruption in surgical training during the COVID-19 pandemic. This was wide-spread and affected all healthcare systems (whether insurance based or funded by public funds) in all participating countries. Thematic analysis revealed the factors perceived by trainees as barriers to training and gave birth to four-point framework of recovery. These are recommendations that can be easily achieved in any country, with minimal resources. Their implementation, however, relies heavily on the active participation and leadership by trainers. Based on the results of the global trainee survey, the authors would like to conduct a Delphi-style survey, addressed to trainers on this occasion, to establish a pragmatic step-by-step approach to improve training during and after the pandemic. This will be a mixed qualitative and quantitative study. Semi-structured interviews will be performed with laparoscopic trainers. These will be transcribed and thematic analysis will be applied. A questionnaire will then be proposed; this will be based on both the results of the semi structured interviews and of the global trainee survey. The questionnaire will then be validated by the steering committee of this group (achieve consensus of >80%). After validation, the questionnaire will be disseminated to trainers across the globe. Participants will be asked to consent to participate in further cycles of the Delphi process until more than 80% agreement is achieved. This study will result in a pragmatic framework for continuation of surgical training during and after the pandemic (with special focus on minimally invasive surgery training).
- 1 January 2021
- Published by AVES YAYINCILIK A.Ş. in Urology Research and Practice
- Vol. 47 (1) , S49-S55
Ablative options for prostate cancer management
This review provides an overview of the available ablative options for prostate cancer (PCa) management. It contemplates the ablative concepts and the role of prostate ablation in different settings, from primary treatment to repeat ablation, and as an alternative to radiorecurrent disease. Improvements in prostate imaging have allowed us to ablate prostate lesions through thermal, mechanical, and vascular-targeted sources of energy. Partial gland ablation (PGA) has an emerging role in the management of localized PCa because toxicity outcomes have been proven less harmful compared with whole-gland treatments. Although long-term oncological outcomes are yet to be consolidated in comparative studies, recent large series and prospective studies in PGA have reported encouraging results. A second ablation after disease recurrence has demonstrated low toxicity, and future studies must define its potential to avoid radical treatments. PGA is an attractive option for PCa management in different scenarios because of its low-toxicity profile. As expected, recurrence rates are higher than those seen in whole-gland procedures. Long-term oncological outcomes of primary and salvage options are required to endorse it among the standard treatments. Cite this article as: Tourinho-Barbosa RR, Batista LT, Cathelineau X, Sanchez-Macias J, Sanchez-Salas R. Ablative options for prostate cancer management. Turk J Urol 2020; 47(Supp. 1): S49-S55.
- 1 January 2021
- Published by AVES YAYINCILIK A.Ş. in Urology Research and Practice
- Vol. 47 (1) , S49-S55
Ablative options for prostate cancer management
This review provides an overview of the available ablative options for prostate cancer (PCa) management. It contemplates the ablative concepts and the role of prostate ablation in different settings, from primary treatment to repeat ablation, and as an alternative to radiorecurrent disease. Improvements in prostate imaging have allowed us to ablate prostate lesions through thermal, mechanical, and vascular-targeted sources of energy. Partial gland ablation (PGA) has an emerging role in the management of localized PCa because toxicity outcomes have been proven less harmful compared with whole-gland treatments. Although long-term oncological outcomes are yet to be consolidated in comparative studies, recent large series and prospective studies in PGA have reported encouraging results. A second ablation after disease recurrence has demonstrated low toxicity, and future studies must define its potential to avoid radical treatments. PGA is an attractive option for PCa management in different scenarios because of its low-toxicity profile. As expected, recurrence rates are higher than those seen in whole-gland procedures. Long-term oncological outcomes of primary and salvage options are required to endorse it among the standard treatments. Cite this article as: Tourinho-Barbosa RR, Batista LT, Cathelineau X, Sanchez-Macias J, Sanchez-Salas R. Ablative options for prostate cancer management. Turk J Urol 2020; 47(Supp. 1): S49-S55.
- 22 May 2020
- Published by Springer Nature in World Journal of Urology
- Vol. 39 (3) , 701-717
Current state of image-guided focal therapy for prostate cancer
Purpose To review the current evidence regarding protocols and outcomes of image-guided focal therapy (FT) for prostate cancer (PCa). Methods A literature search of the latest published studies assessing primary FT for PCa was carried out in Medline and Cochrane library databases followed by a critical review. FT modalities, follow-up strategies, and oncological and toxicity outcomes were summarized and discussed in this review. Results Twenty-four studies with six different sources of energy met the inclusion criteria. A heterogeneity of patient selection, energy sources, treatment templates, and definitions of failure was found among the studies. While a third of patients may be found to have additional cancer burden over 3–5 years following FT, most patients will remain free of a radical procedure. The vast majority of patients maintain urinary continence and good erectile function after FT. Acute urinary retention is the most common complication, whilst severe complications remain rare. Conclusion An increasing number of prospective studies with longer follow-up have been recently published. Acceptable cancer control and low treatment toxicity after FT have been consistently reported. Follow-up imaging and routine biopsy must be encouraged post-FT. While there is no reliable PSA threshold to predict failure after FT, reporting post-FT positive biopsies and retreatment rates appear to be standard when assessing treatment efficacy.
- 22 May 2020
- Published by Springer Nature in World Journal of Urology
- Vol. 39 (3) , 701-717
Current state of image-guided focal therapy for prostate cancer
Purpose To review the current evidence regarding protocols and outcomes of image-guided focal therapy (FT) for prostate cancer (PCa). Methods A literature search of the latest published studies assessing primary FT for PCa was carried out in Medline and Cochrane library databases followed by a critical review. FT modalities, follow-up strategies, and oncological and toxicity outcomes were summarized and discussed in this review. Results Twenty-four studies with six different sources of energy met the inclusion criteria. A heterogeneity of patient selection, energy sources, treatment templates, and definitions of failure was found among the studies. While a third of patients may be found to have additional cancer burden over 3–5 years following FT, most patients will remain free of a radical procedure. The vast majority of patients maintain urinary continence and good erectile function after FT. Acute urinary retention is the most common complication, whilst severe complications remain rare. Conclusion An increasing number of prospective studies with longer follow-up have been recently published. Acceptable cancer control and low treatment toxicity after FT have been consistently reported. Follow-up imaging and routine biopsy must be encouraged post-FT. While there is no reliable PSA threshold to predict failure after FT, reporting post-FT positive biopsies and retreatment rates appear to be standard when assessing treatment efficacy.
- Top Cited PapersOpen Access
- 1 February 2018
- Published by FapUNIFESP (SciELO) in International braz j urol
- Vol. 44 (1) , 14-21
Biochemical recurrence after radical prostatectomy: what does it mean?
Keywords Prostatic Neoplasms; Prostate-Specific Antigen; Prostatectomy
- 1 February 2018
- Published by FapUNIFESP (SciELO) in International braz j urol
- Vol. 44 (1) , 14-21
Top Cited PapersOpen AccessBiochemical recurrence after radical prostatectomy: what does it mean?
Keywords Prostatic Neoplasms; Prostate-Specific Antigen; Prostatectomy
- Open Access
- 1 December 2016
- Published by FapUNIFESP (SciELO) in International braz j urol
- Vol. 42 (6) , 1081-1090
Prostate cancer in Brazil and Latin America: epidemiology and screening
Key words: Prostatic Neoplasms; Epidemiology; Early Diagnosis; Latin America
- 1 December 2016
- Published by FapUNIFESP (SciELO) in International braz j urol
- Vol. 42 (6) , 1081-1090
Open AccessProstate cancer in Brazil and Latin America: epidemiology and screening
Key words: Prostatic Neoplasms; Epidemiology; Early Diagnosis; Latin America